Generally, highly expressed HSP90 shows a positive cytoprotection and the cell viability is decreased by the inhibition or knockdown of HSP90, which is considered to be a feasible therapeutic target in cancer such as colorectal cancer, lung cancer and gliomas [21, 26, 45]. This evidence concerns the gene HSP90AA1 and lung cancer.